TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 1, Issue 2, 2013
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
STUDY ON EFFECT OF METOCLOPRAMIDE IV ON NAUSEA AND VOMITING IN WOMEN UNDERGOING ELECTIVE CAESAREAN DELIVERY UNDER SPINAL ANAESTHESIA
Author
Shaik Hussain Saheb
Email
anatomyshs@gmail.com
keyword
Nausea, Vomiting, Caesarean delivery, Antiemetics, Midazolam, Spinal anaesthesia.
Abstract
The common and distressing symptoms which follow anaesthesia and surgery are pain, nausea and vomiting. Nausea and vomiting have been associated for many years with the use of general anaesthetics for surgical procedures. In spite of the advances like using less emetic anaesthetic agents, improved pre and post operative technique and identification of patient predictive factors, nausea and vomiting still occur with unacceptable frequency in association with surgery and anaesthesia, and is described as “the big little problem”. Antiemetic drugs play an important role in therapy of Nausea and Vomiting. This present study is conducted to find out the antiemetic effect of Metoclopramide. In a randomized single blind manner, 50 women (ASA Grade I and II) undergoing elective caesarean delivery were enrolled for the study with 0.5% hyperbaric bupivacaine 2ml (10mg) spinal anaesthesia. Emetic episodes were recorded during anaesthesia and in the initial period after caesarean delivery (0 – 6hrs). The incidence of patients who were emesis – free in the intraoperative and postoperative period was 39 (78%) with intravenous metoclopramide. No clinically important adverse events were observed. We conclude that use intravenous metoclopramide (10mg) effective for preventing nausea and vomiting in women undergoing caesarean delivery under spinal anaesthesia with bupivacaine (0.5%) hyperbaric.
Download Broucher
Back to Top >>>>